Blue Lake Biotechnology To Present Data For RSV Vaccine Candidate BLB201 In A Late-Breaking Presentation At ISV Annual Congress
Original HTML
ATHENS, Ga. and SAN JOSE, Calif., Oct. 12, 2026 /PRNewswire/ -- Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases, today announced that interim data from the company's Phase 1/2a pediatric clinical trial of RSV vaccine candidate BLB201 will be presented as a late-breaking abstract during the International Society for Vaccines 2026 Annual Congress in Antwerp, Belgium. The oral presentation will include updated safety and immunogenicity data from both RSV-seronegative and RSV-seropositive children ranging in age from eight to 59 months.
Presentation Details
Title: PIV5-vectored Intranasal RSV Vaccine is Safe and Immunogenic in Infants and Young Children
Date/Time: October 12, 2026 17:20 CET
Presenter: Biao He, Ph.D., CEO, Blue Lake Biotechnology
About RSV and BLB201
Respiratory syncytial virus (RSV) is a highly contagious virus that infects over 64 million people worldwide each year. While RSV typically causes mild, cold-like symptoms, it can cause severe and potentially life-threatening disease in infants, older adults, the immunocompromised, and people with certain chronic health conditions. In the U.S., RSV causes up to 80,000 hospitalizations among children under five and up to 160,000 among older adults annually, with up to 10,000 deaths.
BLB201 is an intranasal RSV vaccine candidate being evaluated in Phase 1/2a clinical testing in children ages eight to 59 months. Interim data have indicated that BLB201 may prevent symptomatic RSV infection in young children. BLB201 has received Fast Track designation from the U.S. Food and Drug Administration for prevention of RSV-associated acute respiratory disease in adults over 60 and pediatric populations. BLB201 uses a proprietary PIV5 vector to express the RSV-F protein. PIV5 has been used for decades in canine vaccines and is not known to cause human disease.
About Blue Lake Biotechnology
Blue Lake Biotechnology, Inc. and affiliate CyanVac LLC are developing intranasal vaccines designed to activate mucosal, systemic, and cellular immunity. Our proprietary PIV5 platform mimics natural infection while expressing proteins from targeted pathogens. Our clinical-stage pipeline includes vaccines designed to prevent respiratory infections and overcome limitations of existing vaccine technologies.
Learn more at Blue Lake Biotechnology.
Contact:
Samuel Wu, Chief Business Officer
Blue Lake Biotechnology, Inc. and CyanVac LLC
[email protected]
650-609-2231
SOURCE Blue Lake Biotechnology, Inc.
Share this article
Original Summary
<p>ATHENS, Ga. and SAN JOSE, Calif., Oct. 12, 2026 /PRNewswire/ -- Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious...</p>
Generated Article_json
{"target_audience": "b2b", "is_medical": true, "ai_generated_title": "Blue Lake Presents Interim Pediatric Data for Intranasal RSV Vaccine", "body_html": "<p><strong>Athens, Ga. -- [CURRENT_DATE] --</strong> Blue Lake Biotechnology will present updated interim safety and immunogenicity data for its intranasal RSV vaccine candidate BLB201 as a late-breaking oral abstract at the International Society for Vaccines 2026 Annual Congress in Antwerp, Belgium.</p><h5>Phase 1/2a data cover RSV-seronegative and RSV-seropositive children aged 8 to 59 months</h5><p>The presentation, titled \"PIV5-vectored Intranasal RSV Vaccine is Safe and Immunogenic in Infants and Young Children,\" is scheduled for October 12, 2026 at 17:20 CET. CEO Biao He, Ph.D., will present. Interim data to date have indicated that BLB201 may prevent symptomatic RSV infection in young children.</p><h5>FDA Fast Track designation covers adults over 60 and pediatric populations</h5><p>BLB201 has received Fast Track designation from the U.S. Food and Drug Administration for prevention of RSV-associated acute respiratory disease in adults over 60 and in pediatric populations. The candidate uses a proprietary PIV5 vector to express the RSV-F protein. According to the company, PIV5 has been used for decades in canine vaccines and is not known to cause human disease.</p><h5>RSV burden in the U.S. reaches up to 240,000 hospitalizations a year in the two highest-risk age groups</h5><p>RSV infects more than 64 million people worldwide each year. In the U.S., it causes up to 80,000 hospitalizations among children under five and up to 160,000 among older adults annually, with up to 10,000 deaths. The virus can cause severe, potentially life-threatening disease in infants, older adults, immunocompromised people and those with certain chronic conditions.</p><h5>Blue Lake and affiliate CyanVac target mucosal, systemic and cellular immunity</h5><p>Blue Lake and its affiliate CyanVac LLC are developing intranasal vaccines on the PIV5 platform. The platform is designed to mimic natural infection while expressing proteins from targeted pathogens.</p>", "meta_description": "Blue Lake Biotechnology will present late-breaking Phase 1/2a data on intranasal RSV vaccine BLB201 in children aged 8 to 59 months at ISV 2026 in Antwerp.", "seo_keywords": "Blue Lake Biotechnology, BLB201, RSV vaccine, intranasal vaccine, PIV5, pediatric clinical trial, FDA Fast Track, International Society for Vaccines, CyanVac", "companies": ["Blue Lake Biotechnology", "CyanVac LLC"], "industries": ["Biopharmaceuticals"], "markets_regions": ["United States", "Europe"], "news_type": ["clinical_trial_update", "event_announcement"], "products": ["BLB201"], "themes": ["vaccine_development", "respiratory_disease"], "events": ["International Society for Vaccines 2026 Annual Congress"], "cta_text": "Learn more about Blue Lake Biotechnology and its BLB201 intranasal RSV vaccine program", "learn_more": "", "fact_check": {"accuracy_score": 100, "legal_risk": "low", "corrections_made": [], "recommendation": "publish"}}
Content Hash (SHA-256, erste 32 hex)
7063e79b48cf523ed5e8085dae171020
